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ABSTRACT
Background and Objectives: Whether beta blockers favorably impact the clinical outcome 
in patients with acute myocardial infarction (AMI) remains in debate. We investigated the 
impact of beta blocker on major clinical outcomes during 2 years after percutaneous coronary 
intervention (PCI) in patients with AMI.
Methods: All patients with the first AMI treated with PCI for the period of 2005 to 2014 from 
the Korean National Health Insurance Service claims database were enrolled. We defined 
the regular user as medication possession ratio (MPR) ≥80% and non-user as MPR=0%. We 
compared the occurrence of all cause death, myocardial infarction (MI) and stroke according 
to adherence of beta-blockers. A 1:1 propensity score-matching was conducted to adjust for 
between-group differences.
Results: We identified a total 81,752 patients with met eligible criteria. At discharge, 63,885 
(78%) patients were prescribed beta blockers. For 2 years follow up period, regular users 
were 53,991 (66%) patients, non-users were 10,991 (13%). In the propensity score matched 
population, regular use of beta blocker was associated with a 36% reduced risk of composite 
adverse events (all death, MI or stroke) (hazard ratio [HR], 0.636; 95% confidence interval 
[CI], 0.555–0.728; p<0.001). Compared to no use of beta blocker, regular use significantly 
reduced all death (HR, 0.736; 95% CI, 0.668–0.812; p<0.001), MI (HR, 0.729; 95% CI, 
0.611–0.803; p<0.001) and stroke (HR, 0.717; 95% CI, 0.650–0.791; p<0.001).
Conclusions: Prescription of beta blocker in patients with AMI after PCI was sequentially 
increased. Continuous regular use of beta blocker for 2 years after AMI reduced major adverse 
events compared to no use of beta blocker.
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INTRODUCTION
Beta blockers have been the standard treatment for patients with acute myocardial infarction 
(AMI). Beta blockers have the beneficial effects which reduced ischemia, blood pressure, 
fatal arrhythmia, and thrombosis.1-4) Guidelines had been established mostly based on 
randomized trials before reperfusion era. In the era of percutaneous coronary intervention 
(PCI), there was no prospective randomized trial to show the efficacy of beta blocker therapy 
on clinical outcomes in AMI patients. In addition, several observational studies have showed 
inconsistent results.5)6) With evidences of accumulating recent evidences, practical guidelines 
differ in terms of recommendations regarding indication and duration of beta blockers. In 
addition, continuous use of beta blocker is often impossible due to adverse drug effect. There 
was remained unsolved issue whether beta blocker use beyond 1 year after AMI improved 
outcomes in the reperfusion era. Therefore, we investigated the association of beta blocker 
therapy with clinical outcomes in patients with AMI who underwent PCI, using a nationwide 
cohort study using an insurance claims database.
METHODS
Study population
This study is designed as a retrospective cohort using claim data of Korean National Health 
Insurance Service (KNHIS). The KNHIS as the single insurer of Korean National Health 
Insurance Program (KNHIP) is currently operating a medical claim database including 
not only diagnosis, prescription and procedure but also personal data such as age, gender, 
residential area or the date of death. All of medical service providers and population in Korea 
have an obligation to join the KNHIP according to national acts. Therefore, the KNHIS 
database covers almost all of medical behaviors performed in the whole Korean population 
since 2002. The database is based on Korean Standard Classification of Disease (KCD) 7 code 
system which is very similar with the International Statistical Classification of Diseases and 
Related Health Problems (ICD) 10 code system. From 2005 to 2014, we included the lifetime-
first users of coronary bare metal or drug eluting stent with diagnostic code of AMI (I21, I22 
I23) using the KNHIS database. The exclusion criteria are as follows. 1) no coronary stent 
implantation, 2) cardiopulmonary resuscitation, 3) all death within 3 months, 4) chronic 
obstructive pulmonary disease, 5) previous diagnosis of metastatic cancer. In addition, we 
excluded the patients who never had any anti-platelet agents during follow-up in order to 
minimize the confounding factor related with the loss of follow-up. The study population was 
followed for 2 years or until primary end points after stent implantation.
Measurement of variables
The measurement of variables was performed analyzing diagnostic, prescription and 
procedural code in claim data. We used medical possession rate (MPR) which is calculated 
as dividing prescription duration by follow-up duration in order to identify long-term use 
pattern of beta blocker. We classified study population into regular users (MPR ≥80%), 
irregular users (1–79%), non-users (0%) according to MPR during follow up.7) Baseline 
characteristics of underlying disease were considered pre-diagnosed if individuals had two 
consequent diagnoses in out-patient clinic or a single diagnosis during hospitalization. 
We calculated Charlson comorbidity score which definition was following the Quan's 
previous study.8) The detailed working definitions of all variables in this study are listed in 
Supplementary Table 1. The primary end point of this study is the composite of all-cause 
500https://e-kcj.org https://doi.org/10.4070/kcj.2019.0231
Beta Blockers in Patients with AMI
death, followed myocardial infarction (MI) or all type of stroke. The definition of followed MI 
is the combination of the main diagnosis of AMI (diagnostic code: I21, I22, I23) confirmed by 
coronary angiography (procedure code: HA670) during rehospitalization or newly diagnosed 
sudden cardiac arrest (diagnostic code: I469). We used narrow definition of AMI in order to 
minimize false-positive detection related with misdiagnosis of previous old MI. All types of 
stroke include ischemic, hemorrhagic or unknown type of stroke (diagnostic code: I60–64) 
confirmed with imaging study (examination code: HE101, 201, 135, 235, 236, 451, 461) during 
hospitalization.
Statistical analysis
The χ2 test or Fisher's exact test were used to compare categorical variables. The student 
t-test was conducted to compare continuous variables. Univariate and distributional analysis 
included measures of clinical outcomes. For propensity score matching (PMS), we performed 
a 1:1 case-control match on the propensity score with a hierarchical sequence until no more 
matches made. SAS Logistic procedure code was used to create the propensity score. A 
multivariate Cox proportional-hazards regression model was used to determine the effect of 
beta blocker as an independent predictor of outcomes. Covariates for the adjustment were 
selected using multivariate regression analysis. The following variables were included in the 
Cox proportional-hazard regression model as confounding factors; age, sex, year of study 
enrollment, hypertension, diabetes mellitus, dyslipidemia, previous stroke, previous MI, 
heart failure, history of malignancy, stent type, number of stents, in hospital and followed 
medications (dual antiplatelet, angiotensin II receptor blockers [ARB] or angiotensin 
converting enzyme [ACE] inhibitor, calcium channel blocker, statin, loop diuretics, and 
spironolactone). Statistical analysis was performed using the SAS software (SAS institute, ver 
9.1, Cary, NC, USA). The statistical significance level was p<0.05.
Ethic statement
The study protocol was approved by Chung-Ang University Hospital Institutional Review 
Board (1601-005-254). Informed consent was waived by Institutional Review Board because 
this study was based on the KNHIS database which was fully anonymized.
RESULTS
Prescription rate of beta blocker
We identified a total of 81,752 patients that met eligible criteria for the period between 
January 2005 and December 2014. Overall, 63,885 (78%) patients were prescribed beta 
blockers and 17,867 (22%) were not prescribed at discharge (Tables 1 and 2). There was a 
trend of increase use of beta blockers from 70% in 2005 to 78% in 2014. Among prescribed 
beta blockers at discharge, the most commonly prescribed medication was carvedilol (52%), 
followed by bisoprolol (22%). Overall for 2 years, regular users were 53,991 (66%) of patients 
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Table 1. Trends in the use of beta-blockers during hospitalization in patients with AMI underwent coronary stent insertion













































Overall patients 81,752 5,970 7,598 7,762 7,666 7,998 8,058 8,005 8,714 9,503 10,478
Values are presented as number of patients (%).
AMI = acute myocardial infarction.
and non-users were 10,991 (13%). Regular use of beta blockers has been gradually increased 
from 57% in 2005 to 69% in 2014. During the follow-up, most commonly prescribed agent 
was carvedilol (45%), followed by bisoprolol (24%).
Baseline characteristics
Overall, mean age was 60 years old and male was 76%. (Table 3) The second-generation 
drug eluting stent was deployed in 66% and bare metal stent was used in 4.4%. Single stent 
was implanted in 83% of patients. Prescription rate was 91% of dual antiplatelet therapy, 
78% of ARB or ACE inhibitors and 82% of statin at discharge. Compared with no use of beta 
blockers, regular users were younger, treated more frequently with the second-generation 
drug eluting stent, had more hypertension and less diabetes mellitus and were prescribed 
less dual antiplatelet therapy, more ARBs or ACE inhibitors and statin, less spironolactone 
at discharge. During follow up, regular users were also prescribed more ARBs or ACE 
inhibitors, but less dual antiplatelet therapy and similar spironolactone.
Clinical outcomes
A total of 10,624 patients at each group were matched on the basis of propensity score 
(Table 4). The baseline characteristics after matching were well balanced. In multivariate 
regression analysis, age, sex, underlying disease, type of stents, and medications were 
independent predictors (Table 5). In the matched population, regular beta blocker use was 
associated with a 29% reduced risk of composite adverse events (all death, MI or stroke) 
(hazard ratio [HR], 0.717; 95% confidence interval [CI], 0.650–0.791; p<0.001; Table 6). 
Compared to no use of beta blocker, regular use significantly reduced all death (HR, 0.622; 
95% CI, 0.543–0.714; p<0.001) and MI (HR, 0.705; 95% CI, 0.059–0.842; p=0.001), but did 
not reduce stroke (HR, 1.05; 95% CI, 0.847–1.303; p=0.654).
DISCUSSION
The present study was designed to evaluate whether regular beta blocker use might be 
associated with improved clinical outcome compared with no beta blocker use in patients 
with AMI treated with PCI. In this nationwide ischemic cohort study, regular beta blocker 
prescription improved 2 years clinical outcomes.
Beta-blocker have been reported to reduce fatal arrhythmia, ischemia or infarct size and 
mortality including sudden cardiac death in AMI patients, but most studies had performed 
in the pre reperfusion era.4)9-13) Current guidelines differ in their recommendations for the 
use of beta blocker after AMI. 2014 American Heart Association (AHA)/American College 
of Cardiology (ACC) guideline for non-ST elevation acute coronary syndrome suggests that 
beta blocker therapy is recommended in patients with reduced systolic function as class 
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Table 2. Prescription pattern of beta-blockers in patients with AMI underwent coronary stent implantation
User types Overall 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014


































































Values are presented as number of patients (%).
AMI = acute myocardial infarction.
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Table 3. Baseline characteristics according to pattern of beta blocker use




(n=10,991) p (all 3) p (1 vs.2) p (2 vs.3) p (1 vs.3)
Age (year) 60 (51–69) 61 (51–71) 62 (52–71) - - - -
Male 41,426 (76.73) 12,477 (74.40) 8,243 (75.00) <0.0001 <0.0001 0.2635 <0.0001
Study enrollment <0.0001 <0.0001 <0.0001 <0.0001
2005–2008 17,629 (32.65) 6,229 (37.14) 5,138 (46.75)
2009–2011 16,477 (30.52) 4,945 (29.49) 2,639 (24.01)
2012–2014 19,885 (36.83) 5,596 (33.37) 3,214 (29.24)
Underlying medical condition
Hypertension 26,685 (49.42) 7,944 (47.37) 5,135 (46.72) <0.0001 <0.0001 0.2885 <0.0001
DM 14,656 (27.15) 4,708 (28.07) 3,090 (28.11) 0.0164 0.0185 0.9422 0.0377
Dyslipidemia 14,653 (27.14) 4,494 (26.8) 3,094 (28.15) 0.0392 0.3841 0.0134 0.0302
Previous stroke, all type 3,968 (7.35) 1,564 (9.33) 1,024 (9.32) <0.0001 <0.0001 0.9788 <0.0001
Previous MI 1,728 (3.20) 705 (4.20) 526 (4.79) <0.0001 <0.0001 0.0213 <0.0001
CHF 2,340 (4.33) 912 (5.44) 563 (5.12) <0.0001 <0.0001 0.2511 0.0003
History of malignancy 1,363 (2.52) 518 (3.09) 317 (2.88) 0.0002 <0.0001 0.3289 0.0303
Charlson comorbidity score 1 (0–2) 1 (0–2) 1 (0–2) <0.0001 <0.0001 0.0265 0.0005
≤1 36,729 (68.03) 11,030 (65.77) 7,287 (66.30)
2–3 10,364 (19.20) 3,245 (19.35) 2,149 (19.55)
4–5 4,821 (8.93) 1,640 (9.78) 1,082 (9.84)
≥6 2,077 (3.85) 855 (5.10) 473 (4.30)
Type of stent <0.0001 <0.0001 <0.0001 <0.0001
BMS 2,262 (4.19) 766 (4.57) 592 (5.39)
1st generation DES 14,902 (27.60) 5,262 (31.38) 4,044 (36.79)
2nd generation DES 36,827 (68.21) 10,742 (64.05) 6,355 (57.82)
Number of stents 0.0288 0.0047 0.1918 0.7611
1 4,4670 (82.74) 13,922 (83.02) 9,088 (82.69)
2 6,096 (11.29) 1,770 (10.55) 1,228 (11.17)
≥3 3,225 (5.97) 1,078 (6.43) 675 (6.14)
In-hospital medication
Dual antiplatelet agent 48,896 (90.56) 15,261 (91.00) 10,044 (91.38) 0.0125 0.0881 0.2729 0.0069
RAAS blocker 43,658 (80.86) 12,835 (76.54) 7,149 (65.04) <0.0001 <0.0001 <0.0001 <0.0001
Beta-blocker 48,524 (89.87) 12,850 (76.62) 2,511 (22.85) <0.0001 <0.0001 <0.0001 <0.0001
CCB 2,021 (3.74) 786 (4.69) 630 (5.73) <0.0001 <0.0001 0.0001 <0.0001
Statin 44,834 (83.04) 1,692 (81.65) 8,733 (79.46) <0.0001 <0.0001 <0.0001 <0.0001
High intensity statin 14,755 (27.33) 4,125 (24.60) 2,073 (18.86) <0.0001 <0.0001 <0.0001 <0.0001
Thiazide 1,510 (2.80) 600 (3.58) 402 (3.66) <0.0001 <0.0001 0.7276 <0.0001
Loop diuretics 7,963 (14.75) 3,010 (17.95) 2,033 (18.50) <0.0001 <0.0001 0.2466 <0.0001
Spironolactone 5,683 (10.53) 2,085 (12.43) 1,272 (11.57) <0.0001 <0.0001 0.0316 0.0012
Vasodilators 27,255 (50.48) 8,619 (51.40) 5,935 (54.00) <0.0001 0.0385 <0.0001 <0.0001
Vasopressor 9,322 (17.27) 3,129 (18.66) 2,335 (21.24) <0.0001 <0.0001 <0.0001 <0.0001
Followed medication
Dual antiplatelet agent 31,584 (58.50) 8,369 (49.90) 6,745 (61.37) <0.0001 <0.0001 <0.0001 <0.0001
Aspirin users 15,556 (28.81) 4,276 (25.50) 2,693 (24.50)
Clopidogrel users 6,363 (11.79) 1,760 (10.49) 1,008 (9.17)
No antiplatelet agents 488 (0.90) 2,365 (14.10) 545 (4.96)
RAAS blocker 39,369 (72.92) 6,784 (40.45) 6,089 (55.40) <0.0001 <0.0001 <0.0001 <0.0001
CCB 4,192 (7.76) 967 (5.77) 1,026 (9.33) <0.0001 <0.0001 <0.0001 <0.0001
Statin 46,501 (86.13) 8,948 (53.36) 7,991 (72.70) <0.0001 <0.0001 <0.0001 <0.0001
High intensity statin 11,962 (22.16) 3,329 (19.85) 1,541 (14.02) <0.0001 <0.0001 <0.0001 <0.0001
Thiazide 2,580 (4.78) 498 (2.97) 569 (5.18) <0.0001 <0.0001 <0.0001 0.0762
Loop diuretics 5,535 (10.25) 1,287 (7.67) 1,195 (10.87) <0.0001 <0.0001 <0.0001 0.0515
Spironolactone 3,014 (5.58) 571 (3.40) 612 (5.57) <0.0001 <0.0001 <0.0001 0.9528
Vasodilators 18,320 (33.93) 3,999 (23.85) 4,088 (37.19) <0.0001 <0.0001 <0.0001 <0.0001
Number of antihypertensives 1.85±0.59 0.49±0.62 0.70±0.67 <0.0001 <0.0001 <0.0001 <0.0001
Number of antihypertensives 2 (2–2) 0 (0–1) 1 (0–1) - - - -
Values are expressed as median (interquartile range), number (%), or mean±standard deviation.
BMS = bare metal stent; CCB = calcium channel blocker; CHF = congestive heart failure; DES = drug-eluting stent; DM = diabetes mellitus; MI = myocardial 
infarction; RAAS = Renin-angiotensin-aldosterone system.
I, level of evidence C and in patients with normal left ventricular (LV) function as class 
IIa, level of evidence C.14) 2013 AHA/ACC guideline for ST-elevation myocardial infarction 
(STEMI) suggests that beta blocker should be continued during and after hospitalization for 
all patients and with no contraindications.15) Similarly, 2017 European Society of Cardiology 
(ESC) guideline for STEMI suggests that routine oral beta blocker treatment should be 
considered during and after hospitalization in all patients without contraindications (Class 
IIa, level of evidence C).16) 2011 AHA/American College of Cardiology Foundation (ACCF) 
Secondary prevention and risk reduction therapy for patients with coronary and other 
atherosclerotic vascular disease recommended beyond 3 years of beta blocker therapy in 
AMI patients with normal LV function.17) There is no randomized controlled trial to show 
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Table 4. Baseline characteristics before and after propensity score matching
Risk factors









Followed duration (month) 24.33 (21.43–24.33) 24.33 (18.03–24.33) 0.14 - 24.33 (21.53–24.33) 24.33 (18.07–24.33) 0.11 -
Age (year) 60 (51–69) 62 (52–71) −0.15 - 62 (52–71) 61 (52–71) −0.01 -
Male 41,426 (76.73) 8,243 (75.00) 0.03 <0.0001 7,988 (75.19) 7,991 (75.22) 0.00 <0.0001
Study enrollment <0.0001 0.8109
2005–2008 17,629 (32.65) 5,138 (46.75) −0.24 4,886 (45.99) 4,930 (46.40) −0.01
2009–2011 16,477 (30.52) 2,639 (24.01) 0.12 2,589 (24.37) 2,557 (24.07) 0.01
2012–2014 19,885 (36.83) 3,214 (29.24) 0.13 3,149 (29.64) 3,137 (29.53) 0.00
Underlying medical condition
Hypertension 26,685 (49.42) 5,135 (46.72) 0.04 <0.0001 5,058 (47.61) 4,989 (46.96) 0.01 <0.0001
DM 14,656 (27.15) 3,090 (28.11) −0.02 0.0377 2,993 (28.17) 2,975 (28.00) 0.00 <0.0001
Dyslipidemia 14,653 (27.14) 3,094 (28.15) −0.02 0.0302 3,041 (28.62) 3,006 (28.29) 0.01 <0.0001
Previous stroke, all type 3,968 (7.35) 1,024 (9.32) −0.06 <0.0001 993 (9.35) 969 (9.12) 0.02 <0.0001
CHF 1,728 (3.20) 526 (4.79) −0.07 <0.0001 505 (4.75) 493 (4.64) 0.02 <0.0001
ESRD 2,340 (4.33) 563 (5.12) −0.03 0.0003 532 (5.01) 538 (5.06) −0.01 <0.0001
History of malignancy 1,363 (2.52) 317 (2.88) −0.02 0.0303 312 (2.94) 304 (2.86) 0.02 <0.0001
Charlson comorbidity score 1 (0–2) 1 (0–2) −0.04 - 1 (0–2) 1 (0–2) 0.01 -
≤1 36,729 (68.03) 7,287 (66.3) 0.03 0.0005 7,006 (65.95) 7,054 (66.40) −0.01 0.8917
2–3 10,364 (19.20) 2,149 (19.55) −0.01 2,091 (19.68) 2,078 (19.56) 0.00
4–5 4,821 (8.93) 1,082 (9.84) −0.03 1,068 (10.05) 1,041 (9.80) 0.01
≥6 2,077 (3.85) 473 (4.30) −0.02 459 (4.32) 451 (4.25) 0.00
Type of stent <0.0001 0.1590
BMS 2,262 (4.19) 592 (5.39) −0.05 514 (4.84) 573 (5.39) −0.02
1st generation DES 14,902 (27.60) 4,044 (36.79) −0.16 3,948 (37.16) 3,887 (36.59) 0.01
2nd generation DES 36,827 (68.21) 6,355 (57.82) 0.18 6,162 (58.00) 6,164 (58.02) 0.00
Number of stents 0.7611 0.4762
1 44,670 (82.74) 9,088 (82.69) 0.00 8,736 (82.23) 8,786 (82.70) −0.01
2 6,096 (11.29) 1,228 (11.17) 0.00 1,196 (11.26) 1,188 (11.18) 0.00
≥3 3,225 (5.97) 675 (6.14) −0.01 692 (6.51) 650 (6.12) 0.01
Followed medication
Dual antiplatelet agent 31,584 (58.50) 6,745 (61.37) −0.05 <0.0001 6,686 (62.93) 6,725 (63.30) −0.01 0.0001
Aspirin users 15,556 (28.81) 2,693 (24.50) 0.08 2,653 (24.97) 2,690 (25.32) −0.01
Clopidogrel users 6,363 (11.79) 1,008 (9.17) 0.07 983 (9.25) 1,007 (9.48) −0.01
No antiplatelet agents 488 (0.90) 545 (4.96) −0.23 302 (2.84) 202 (1.90) 0.05
RAAS blocker 39,369 (72.92) 6,089 (55.40) 0.31 <0.0001 6,163 (58.01) 6,082 (57.25) 0.01 <0.0001
CCB 4,192 (7.76) 1,026 (9.33) −0.05 <0.0001 1,024 (9.64) 1,015 (9.55) 0.01 <0.0001
Statin 46,501 (86.13) 7,991 (72.70) 0.29 <0.0001 8,061 (75.88) 7,979 (75.10) 0.01 <0.0001
High intensity statin 11,962 (22.16) 1,541 (14.02) 0.17 <0.0001 1,505 (14.17) 1,521 (14.32) −0.01 <0.0001
Thiazide 2,580 (4.78) 569 (5.18) −0.02 0.0762 598 (5.63) 561 (5.28) 0.05 <0.0001
Loop diuretics 5,535 (10.25) 1,195 (10.87) −0.02 0.0515 1,232 (11.60) 1,184 (11.14) 0.03 <0.0001
Spironolactone 3,014 (5.58) 612 (5.57) 0.00 0.9528 609 (5.73) 604 (5.69) 0.01 <0.0001
Vasodilators 18,320 (33.93) 4,088 (37.19) −0.06 <0.0001 4,069 (38.30) 4,035 (37.98) 0.01 <0.0001
Values are expressed as median (interquartile range) or number (%).
BMS = bare metal stent; CCB = calcium channel blocker; CHF = congestive heart failure; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage 
renal disease; RAAS = Renin-angiotensin-aldosterone system; SD = standard deviation.
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Table 5. Univariate and multivariate predictors of composite outcomes (all-cause mortality, MI or stroke) after coronary stenting in MI
Risk factors
Univariate Multivariate
HR 95% CI p HR 95% CI p
Age 1.057 1.055–1.059 <0.0001 1.045 1.042–1.047 <0.0001
Male 0.580 0.549–0.612 <0.0001 1.168 1.099–1.241 <0.0001
Study enrollment
2005–2008 1 - - 1 - -
2009–2011 0.845 0.794–0.901 <0.0001 1.155 1.063–1.254 0.0006
2012–2014 0.746 0.700–0.794 <0.0001 1.050 0.955–1.153 0.3122
Underlying medical condition
Hypertension 1.987 1.881–2.099 <0.0001 1.167 1.095–1.245 <0.0001
DM 1.867 1.770–1.969 <0.0001 1.215 1.131–1.304 <0.0001
Dyslipidemia 1.239 1.171–1.311 <0.0001 0.895 0.840–0.952 0.0005
Previous stroke, all type 2.956 2.767–3.158 <0.0001 1.498 1.388–1.616 <0.0001
Previous MI 2.239 2.027–2.473 <0.0001 1.246 1.124–1.380 <0.0001
CHF 2.761 2.542–2.999 <0.0001 1.327 1.212–1.453 <0.0001
History of malignancy 2.190 1.952–2.457 <0.0001 1.293 1.133–1.476 0.0001
Charlson comorbidity score 1.214 1.202–1.227 <0.0001 1.038 0.994–1.083 0.0905
≤1 1 - - 1 - -
2–3 1.663 1.557–1.776 <0.0001 1.065 0.957–1.185 0.2465
4–5 2.435 2.259–2.625 <0.0001 1.115 0.935–1.330 0.2252
≥6 3.565 3.260–3.899 <0.0001 1.191 0.894–1.589 0.2327
Type of stent
BMS 1 - - 1 - -
1st generation DES 0.853 0.760–0.956 0.0063 0.824 0.731–0.928 0.0014
2nd generation DES 0.624 0.558–0.697 <0.0001 0.634 0.563–0.715 <0.0001
Number of stents
1 1 - - 1 - -
2 1.047 0.964–1.138 0.2731 0.913 0.840–0.992 0.0323
≥3 1.187 1.072–1.314 0.0010 0.925 0.828–1.034 0.1698
Followed medication
Dual antiplatelet agent 3.949 3.622–4.306 <0.0001 3.657 3.352–3.99 <0.0001
Aspirin users 1 - - 1 - -
Clopidogrel users 1.284 1.118–1.474 0.0004 1.155 1.005–1.327 0.0418
No antiplatelet agents 6.430 5.715–7.233 <0.0001 2.847 2.513–3.224 <0.0001
RAAS blocker 0.561 0.532–0.591 <0.0001 0.733 0.692–0.777 <0.0001
CCB 0.789 0.708–0.879 <0.0001 0.693 0.621–0.774 <0.0001
Statin 0.360 0.341–0.379 <0.0001 0.502 0.473–0.534 <0.0001
High intensity statin 0.799 0.745–0.857 <0.0001 1.187 1.102–1.278 <0.0001
Thiazide 0.907 0.795–1.035 0.1458 0.826 0.722–0.944 0.0051
Loop diuretics 2.294 2.146–2.452 <0.0001 1.349 1.250–1.457 <0.0001
Spironolactone 1.948 1.778–2.135 <0.0001 1.278 1.154–1.416 <0.0001
Vasodilators 1.076 1.018–1.138 0.0096 1.009 0.953–1.069 0.7480
Regular user 1 - - 1 - -
Irregular user 1.983 1.867–2.105 <0.0001 1.316 1.230–1.407 <0.0001
No user 1.853 1.726–1.990 <0.0001 1.380 1.282–1.485 <0.0001
BMS = bare metal stent; CI = confidence interval; CCB = calcium channel blocker; CHF = congestive heart failure; DES = drug-eluting stent; DM = diabetes 
mellitus; ESRD = end-stage renal disease; HR = hazard ratio; MI = myocardial infarction; RAAS = Renin-angiotensin-aldosterone system; SD = standard deviation.
Table 6. Outcomes after matching
Patterns of beta blocking















All death 1,873.32 345 3.70 2,952.40 525 5.53 0.825 0.720–0.946 0.0060
Followed MI 1,151.14 212 2.22 1,608.35 286 3.02 0.900 0.836–0.969 0.0052
Followed stroke 955.67 176 1.88 894.15 159 1.72 0.903 0.839–0.972 0.0068
Composite of MI or stroke 2,095.95 386 4.04 2,496.88 444 4.67 0.897 0.833–0.966 0.0038
Composite of all death, MI or stroke 3,871.53 713 7.41 5,269.33 937 9.62 0.965 0.926–1.006 0.0938
Revascularization 7,422.70 1,367 13.36 8,261.09 1,469 14.61 0.960 0.921–1.000 0.0508
All re-hospitalization 24,733.27 4,555 46.91 25,396.24 4,516 46.69 0.951 0.913–0.991 0.0173
CI = confidence interval; HR = hazard ratio; MI = myocardial infarction.
the efficacy of beta blocker in PCI era. Evidence supporting routine beta blocker therapy 
following by AMI was lacking in reperfusion era. Beta-blockers did not reduce mortality at 
1 year after AMI in patients with heart failure or ventricular dysfunction.5) However, only 
approximate half of enrolled patients underwent coronary intervention and prescription 
data was based on point at discharge. A recent meta-analysis which included studies since 
2000 showed that beta blocker therapy was not associated to reduce mortality following 
AMI.18) Conversely, from a registry data, beta blocker at discharge significantly reduced all 
cause death at 1 year after STEMI in patients treated primary PCI.6) The results from previous 
studies are inconsistent. Our result of all comer nationwide KNHI database was in line with 
recommendations from current guidelines for beta blockers therapy in patients with AMI, 
even after PCI.
Effective duration of beta blocker therapy after AMI has been still unveiled. A single center 
retrospective study investigated the effect of beta blocker according to the durations of 
prescription on clinical outcome.19) Beta-blocker therapy after AMI had beneficial effect until 
1 years with 29% of mortality reduction, but beta blocker prescription at 1 and 3 years after 
AMI could not reduce mortality. In addition, 5-year mortality was not significantly decreased 
in patients who were taking beta blockers at 1 year.20) Most studies had performed based 
on the information of medication at discharge or small sample size. A few studies tried to 
provide data of medication at some period point, but not of continued use of the beta blocker. 
In this study, it is meaningful to compare the patients who were consistently prescribed 
during follow-up period with patients who never prescribed beta blockers. In contemporary 
reperfusion era, early revascularization, antiplatelet therapy, ARB or ACE inhibitor, and lipid 
lowering therapy may likely attenuate the mortality benefit of beta blockers in post AMI. 
However, this nationwide cohort study showed that beta blocker therapy was associated with 
mortality reduction at least for 2 years in AMI patients treated with PCI.
A number of limitations must be acknowledged in this study. First of all, there was raised 
question about the accuracy of the AMI definition using the KCD-10 codes in KNIH claims 
database. AMI was validated in a previous study with the accuracy of 73%.21) However, we 
defined AMI as if patients underwent PCI with AMI diagnosis so that the accuracy of diagnosis 
might be much higher. Diagnosis of AMI was not differentiated into STEMI and non-STEMI due 
to intrinsic limitation of database. Also, death was defined as the situational status, including 
hospital death and out of hospital death based on the loss of KNIH qualification. There was a 
chance of not accurate diagnosis. Uncontrolled covariates may exist. Secondly, this study was 
not a result of a randomized controlled trial. Consequently, the risk factors not included in 
the parameters could potentially affect the result. For example, patients who did not receive 
beta blocker were sicker or at higher risk. Furthermore, we defined regular use as MPR ≥80% 
but true drug adherence would depend on each patient. There is a possibility to overestimate 
the effect of beta blocker. Third, we could not adjust several variables, such as LV ejection 
fraction and time point of primary PCI in patients with STEMI, due to the intrinsic limitation 
of database. Even though we tried to adjust LV systolic dysfunction using prescription of loop 
diuretics and spironolactone, the results could be affected by LV function. Despite these 
limitations, the strength of this study is a large population based all comer dataset to determine 
the role of beta blocker after PCI in patients with AMI.
In conclusion, use of beta blocker in patients with AMI after PCI was subsequently increased 
from 2005 to 2014 in Korea. Regular use of beta blocker for 2 years after PCI in AMI patients 
was associated with improved clinical outcomes compared to no use of beta blocker.
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